Northern Trust Corp Prelude Therapeutics Inc Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Northern Trust Corp holds 106,377 shares of PRLD stock, worth $138,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,377

Previous 124,686 14.68%

Holding current value

$138,290

Previous $475,000 53.68%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.07 - $6.37 $37,899 - $116,628	-18,309 Reduced 14.68%	106,377 $220,000
Q2 2024 Aug 14, 2024	BUY	$3.32 - $5.63 $8,429 - $14,294	2,539 Added 2.08%	124,686 $475,000
Q1 2024 May 14, 2024	BUY	$2.68 - $4.84 $21,574 - $38,962	8,050 Added 7.06%	122,147 $578,000
Q4 2023 Feb 13, 2024	SELL	$1.69 - $4.37 $2,401 - $6,209	-1,421 Reduced 1.23%	114,097 $487,000
Q3 2023 Nov 13, 2023	BUY	$2.74 - $4.79 $92,949 - $162,491	33,923 Added 41.57%	115,518 $356,000
Q2 2023 Aug 11, 2023	BUY	$4.45 - $8.12 $268,904 - $490,675	60,428 Added 285.48%	81,595 $367,000
Q2 2022 Aug 12, 2022	SELL	$4.0 - $7.55 $322,956 - $609,579	-80,739 Reduced 79.23%	21,167 $110,000
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $36,418 - $69,775	-5,278 Reduced 4.92%	101,906 $703,000
Q4 2021 Feb 08, 2022	BUY	$11.89 - $31.74 $9,024 - $24,090	759 Added 0.71%	107,184 $1.34 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $38.65 $315,856 - $473,539	-12,252 Reduced 10.32%	106,425 $3.33 Million
Q2 2021 Aug 13, 2021	BUY	$28.63 - $44.3 $90,986 - $140,785	3,178 Added 2.75%	118,677 $3.4 Million
Q1 2021 May 12, 2021	BUY	$39.27 - $91.68 $18,692 - $43,639	476 Added 0.41%	115,499 $5.01 Million
Q4 2020 Feb 11, 2021	BUY	$28.81 - $88.94 $3.31 Million - $10.2 Million	115,023 New	115,023 $8.23 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.7M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Prelude Therapeutics Inc Transaction History